You are here: Geisinger Medical
Laboratories > Test
Catalog
Geisinger Medical Laboratories Test Catalog
PRE-EMPLOYMENT DRUG SCREEN W/ CONFIRMATION
|
|||||||||||||||||
ORDERING INFORMATION: |
Geisinger Epic Procedure Code: LAB3451 Geisinger Epic ID: 109406 | ||||||||||||||||
SPECIMEN COLLECTION |
|||||||||||||||||
Specimen type: |
Random urine | ||||||||||||||||
Preferred collection container: |
|||||||||||||||||
Specimen required: |
20 mL urine; minimum 10 mL. Consult with Toxicology Laboratory if specimen volume is less than minimum requirement. | ||||||||||||||||
| SPECIMEN PROCESSING |
|||||||||||||||||
Specimen processing instructions: |
Must follow forensic processing protocol. | ||||||||||||||||
Transport temperature: |
Refrigerated (preferred) or room temperature. | ||||||||||||||||
Specimen stability: |
Room temperature: 2 days. Refrigerated: 14 days. | ||||||||||||||||
Rejection criteria: |
Stability limits exceeded. Deviation from chain of custody (consult with Toxicology Laboratory). | ||||||||||||||||
TEST DETAILS |
|||||||||||||||||
Reference interval: |
Negative. Screen cutoff concentration:
|
||||||||||||||||
CPT code(s): |
80307 | ||||||||||||||||
| Note: The billing party has sole responsibility for CPT coding. Any questions regarding coding should be directed to the payer being billed. The CPT codes provided by GML are based on AMA guidelines and are for informational purposes only. | |||||||||||||||||
Test includes: |
Amphetamines screen Cannabinoids screen Cocaine metabolite screen Heroin screen Hydrocodone screen Morphine/Codeine screen Oxycodone screen Cotinine screen Specimen validity test Positive screening results are automatically confirmed at an additional charge. |
||||||||||||||||
Methodology: |
EMIT KIMS |
||||||||||||||||
Synonyms: |
Forensic drugs of abuse test
|
||||||||||||||||
Clinical significance: |
Used to detect the presence of various classes of drugs in human urine. | ||||||||||||||||
Doctoral Director(s:) |
Hoi-Ying Elsie Yu, PhD, DABCC Sheng-Ying (Margaret) Lo, PhD, DABCC |
||||||||||||||||
| Review Date: | 12/29/2022 | ||||||||||||||||